Chromosomal Damage in Type 2 Diabetes Patients (MIKRODIAB)

University of Vienna

Status: Unknown

Conditions: Cancer; Type 2 Diabetes

Study type: Observational

Funder types: Other

Identifiers

NCT02231736

UNIVIE-549-1

Details and patient eligibility

About

The purpose of the study is to determine whether glycemic control (HbA1c) is linked to chromosomal damage in type 2 Diabetes patients

Enrollment: 130 estimated patients

Sex: Female

Ages: 30+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 Diabetes (T2DM)
• Sex: female
• Age: > 30years
• Medication: oral anti-diabetics and/or Insulin therapy
• Constant nutritional behavior, constant physical activity, constant weight for the last 4 weeks
• Non-smoking for at least 1 year

Exclusion criteria

• Patients with type 1 DM
• Age: < 30years
• Pregnant or lactating women
• Participation in another clinical trial
• Change of medication in regard to metabolic parameters within the last 4 weeks
• Significant cardiovascular damage with NYHA > III
• Liver disease with three-times higher transaminase values
• Chronic kidney disease with serum creatinine > 2 mg/dl
• Dialysis
• HIV positive
• History of chronic alcohol abuse in the last two years
• History of cancer, stroke, organ transplantation
• Male

Trial design

130 participants in 2 patient groups

Type 2 diabetes, HbA1c>7.5

Type 2 diabetes, HbA1c<7.5